- Details
- Phillip Koo joins Neal Shore to discuss radium 223 for treating men with metastatic castration-resistant prostate cancer. Radium-223 has improved overall survival (OS) and reduced symptomatic skeletal events (SSE) in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases (ALSYMPCA trial). The survival benefit and the safety and tolerability profile of radium-223...
|
- Details
- Sipuleucel-T (Provenge ® ) has been FDA approved since 2010 in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). The IMPACT (Immunotherapy for Prostate AdenoCarcinoma Treatment), was a randomized, double-blind, placebo-controlled study of 512 men with metastatic, hormone-refractory prostate cancer. Initially, the targeted patients were those wi...
|
- Details
- Bertrand Tombal discusses the ongoing PEACE III trial evaluating enzalutamide alone versus enzalutamide plus radium-223 post the ERA-223 data. The interim safety analysis was presented at ASCO and the data demonstrated that there was an increase fracture rate with the addition of radium-223 to enzalutamide prior to mandating the use of bone protecting agents. Pathological and non-pathological frac...
|
- Details
- Alicia Morgans, Charles Ryan, and Neal Shore discuss the clinical evidence and considerations in treating prostate cancer progression as patients fail first-line treatment in the nmCRPC and advance to metastatic castration-resistant prostate cancer (mCRPC). They highlight the need to change the mechanism of action and the opportunities that each Sipuleucel-T, (Provenge®) an autologous cellular imm...
|
- Details
- Nick Vogelzang discusses a brief history of the advancements in treating prostate cancer. He provides background on how we have arrived at where we are now with the advances in both the diagnosis and treatment of prostate cancer while talking with Alicia Morgans. Dr. Vogelzang reflects upon the time when we were relegated to using primitive bone scans to define disease to the current era of advanc...
|
- Details
- Kelvin Moses explores the clinical benefit of sipuleucel-T treatment in African American men with advanced prostate cancer in this conversation with Alicia Morgans. A large volume of evidence has demonstrated that African American men have an increased risk of developing mCRPC and have higher mortality as compared with Caucasian men. Sipuleucel-T has demonstrated a survival benefit in men with met...
|
- Details
- Alicia Morgans invites Tia Higano to discuss data analysis amongst patients with mCRPC who were enrolled in the Flatiron Health prostate cancer registry from 2013-2017. Findings include the discovery that 77% of patients receive some form of life-prolonging therapy and that only 60% of the patients ever received either denosumab or zoledronic acid. Alicia and Tia conclude by stating the importance...
|
- Details
- Susan Halabi discusses new findings in the evaluation of racial disparities in progression-free survival across nine trials. Biographies: Susan Halabi Ph.D Professor of Biostatistics and Bioinformatics. Duke Cancer Institute Alicia Morgans, MD, MPH , Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinoi...
|
- Details
- Martin Felices discusses a unique approach to using natural killer (NK) cells to target a variety of cancers. NK cells seek out abnormal cells while also producing inflammatory cytokines that induce the adaptive immune response. There is a known role of NK cells in hematologic malignancies whereas in tumor micro environments the NK cells display characteristics of exhaustion and lack of maturation...
|
- Details
- Neal Shore and Oliver Sartor cover the topic of racial disparities in prostate cancer and the use of immunotherapy particularly sipuleucel-T in the African American community. Oliver does a deep dive into the double-blind, placebo-controlled, multicenter trial, Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) study, involving 512 men with metastatic castration-resistant prostate cancer...
|
